Sensydia: Non-Invasive Cardiac Diagnostic Company Secures $3 Million NIH Grant
/Sensydia – a non-invasive cardiac diagnostic company – announced recently that it was awarded a Fast-Track Small Business grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH). This award provides Sensydia with non-dilutive funding for the development and clinical testing of the machine learning algorithms for the Cardiac Performance System (CPS), which was designed to enable earlier detection and therapy guidance for patients with heart failure and pulmonary hypertension.
The Phase I of the grant proposal is budgeted for approximately $600,000 and Phase II for $2.4M, following the successful completion of Phase I milestones. And this NIH award marks a significant milestone for Sensydia, a company committed to developing AI-based solutions for the diagnosis and management of cardiopulmonary diseases. Sensydia recently raised $8M in venture funding.